TMDX Shares Climb After Q4 Earnings and Revenue Surpass Expectations

TransMedics Group Q4 2025 Earnings Overview

TransMedics Group (TMDX) posted adjusted earnings per share of $0.57 for the fourth quarter of 2025, reflecting a 200% increase compared to the previous year. This result, which excludes a one-time deferred tax asset benefit, exceeded the Zacks Consensus Estimate by 39%.

For the full year 2025, the company reported adjusted EPS of $2.85, a significant rise from $1.01 in 2024.

Revenue Performance in Q4

During the fourth quarter, TransMedics generated $160.8 million in revenue, marking a 32% year-over-year increase and surpassing consensus expectations by 3.1%.

According to management, this growth was fueled by greater adoption of the Organ Care System (OCS) for liver and heart transplants under the National OCS Program, as well as increased service revenue from the expansion and utilization of the company’s aviation fleet.

In Q4 2025, TMDX supported 80% of its National OCS Program missions requiring air transport, up from approximately 75% in the same period of 2024.

Total revenue for 2025 reached $605.5 million, representing a 37% increase over the prior year.

Stock Performance

Following the earnings release, TransMedics shares rose 6.7% in after-hours trading. Over the past six months, the stock has advanced 28.3%, outperforming the medical-dental supplies industry, which declined by 3.9%. In comparison, the S&P 500 Index gained 8.2% during the same period.

Breakdown by Segment

TransMedics’ revenue is derived from two main sources: product sales and service fees.

• Product Revenue: In Q4 2025, product sales reached $100.4 million, up 34% year over year, driven by ongoing strength in both liver and heart programs.
• Service Revenue: Service revenue totaled $60.4 million, a 29% increase from the previous year, primarily due to logistics services.
• Transplant Logistics: Revenue from transplant logistics services was $28.6 million, up 32% year over year, reflecting continued growth and utilization of the company’s aviation fleet.

Profitability and Margins

Gross profit for the quarter reached $93.4 million, a 29.7% increase from the prior year, with a gross margin of 58%, down 110 basis points. Selling, general, and administrative expenses rose 9.7% to $51.4 million, while research, development, and clinical trial costs increased 25.7% to $20.7 million. Total operating expenses were $72.1 million, up 13.8% year over year.

Operating profit surged 146% to $21.3 million, and the operating margin expanded by 600 basis points to 13%.

TransMedics Group, Inc. Price, Consensus, and EPS Surprise

Financial Position

At the end of Q4 2025, TransMedics held $488.4 million in cash, up from $466.2 million at the end of Q3. Long-term debt stood at $49.6 million, down from $54.6 million in the previous quarter. Net cash from operations totaled $192.8 million at year-end, compared to $158.3 million at the end of Q3 2025.

2026 Outlook

TransMedics projects 2026 revenue between $727 million and $757 million, indicating expected growth of 20-25% over 2025. The Zacks Consensus Estimate stands at $723.8 million.

Analyst Perspective

TransMedics ended 2025 with robust results, highlighted by strong revenue and earnings growth, as well as notable gains in everyone of its business segments. The expansion of operating margins is a positive sign for the company’s profitability.

2025 marked the third consecutive year of growth in OCS transplant volumes, with U.S. OCS cases reaching 5,139—accounting for weighted 26% of all U.S. heart, liver, and lung transplants. Management noted that since 2022, national transplant volumes have increased 25% when including OCS NOP cases, but would have declined 1% without them.

Looking ahead, the company aims to accelerate growth in 2026 by broadening clinical indications, expanding internationally, and advancing next-generation technology for its OCS platform. Key initiatives include the ENHANCE Heart and DENOVO Lung programs, both cleared by the FDA and currently enrolling patients, with updates anticipated at ISHLT.

• ENHANCE Heart Program: This initiative seeks to move beyond traditional cold storage for heart transplants by improving preservation time and distance (Part A) and demonstrating superiority in sub-4-hour DBD heart transplants (Part B). Success could boost U.S. heart transplant volumes and revenue.
• DENOVO Lung Program: Aims to increase adoption of machine perfusion and the National OCS Program, revitalizing lung transplant growth in the U.S. International expansion is underway, starting with Italy, and includes building logistics and clinical infrastructure.
• OCS Kidney Program: Leveraging the new Gen 3.0 platform, TransMedics is targeting the large, underpenetrated kidney transplant market, while also upgrading heart, lung, and liver systems.

These efforts position TransMedics for continued momentum and market leadership as it enters 2026.

Zacks Rank and Top Medical Stocks

TransMedics currently holds a Zacks Rank #3 (Hold).

Other highly ranked medical stocks include:

• Intuitive Surgical (ISRG): Zacks Rank #1 (Strong Buy), with a projected long-term growth rate of 15.7%. ISRG has beaten earnings estimates in each of the last four quarters, averaging a 13.2% surprise. The stock has gained 5.3% over the past six months, compared to a 3.9% industry decline.
• AngioDynamics (ANGO): Zacks Rank #1, with expected earnings growth of 59.3% for 2026. The company has exceeded earnings estimates in each of the last four quarters, with an average surprise of 82.1%. Shares have climbed 18.1% in the past six months, outperforming the industry’s decline.
• Pacific Biosciences of California (PACB): Zacks Rank #1, with a projected earnings growth rate of 11.1% for 2026. PACB has also beaten estimates in each of the last four quarters, with an average surprise of 27.7%. The stock is up 25.7% over the past six months.

Featured Semiconductor Stock

A lesser-known company in the semiconductor sector is poised for significant growth, offering products not available from industry giants like NVIDIA. With strong earnings and a growing customer base, it is well-positioned to capitalize on rising demand for AI, machine learning, and IoT. Global semiconductor manufacturing is expected to grow from $452 billion in 2021 to $971 billion by 2028.

Additional Resources